Amgen and AstraZeneca has announced that AMAGINE-3™, a pivotal, multi-arm Phase 3 trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In